The World Post
Going forward, we need to be better prepared for further outbreaks of this and other infectious agents. Maybe someday in the future, Ebola will be sealed and contained in a building. But in the modern age, even such containment is only temporary.
The current Ebola epidemic, the worst on record, has killed nearly 5,000 people since March, mostly in the West African countries
Amgen will assign 12 to 14 employees to the effort, said spokeswoman Kristen Davis, and they will work on the project through
Supply: Tekmira CEO Mark J. Murray said that supplies of the drug are “limited,” reports the Wall Street Journal. Testing
Black Voices
Civil rights leader Jesse Jackson was tactful and circumspect when he questioned the way health officials and medical staffers handled the care and treatment of Ebola victim Thomas Duncan. Jackson carefully avoided using the "R" word.
While many difficult scientific issues remain to be resolved, one thing is clear: WHO and its scientific and industry partners are making sure that no stone is left unturned, that no international standards for safety and quality are compromised.
The use of ZMapp raises the question of privilege. Is it only those with better connections to positions of power who will get a fighting chance to receive this experimental drug?
If a condition, even Ebola, threatens your life, be courageous, be informed, and be prepared to make a decision that could help you survive.
Take, for instance the porcine epidemic diarrhea (PED) viruses that was expected to kill more than 5 million pigs back in
The drug contains three antibodies, which are molecules that can bind to a foreign protein. Several studies on mice and guinea
The need for these drugs is greatest in the countries where the epidemic is raging. Their residents come first. Because clinical trials for safety and efficacy can be carried out only in such countries, even the "compassionate use" of an unproven drug in severely limited supply should be granted first to inhabitants of the nations that have been most severely affected.
Luckily, the two Americans who received ZMapp, the new experimental drug for Ebola, seem to be improving, which holds great promise and hope for thousands of other people but also raises broader ethical issues and questions.
Geisbert said he isn’t sure if increased awareness of Ebola will push Big Pharma to develop a cure, but he’s already seen
Dr. Kent Brantly and Nancy Winebol, who both contracted the Ebola disease, have reportedly shown improvement in the last couple of days after receiving a second dose of the experimental drug ZMapp.
There is no cure or established treatment for Ebola, only experimental treatments that are still being researched. An experimental